AI boosts accuracy when discriminating between malignant and benign ovarian tumors on MRI

A machine learning model that incorporates both clinical and radiomic features could prove beneficial to radiologists differentiating between benign and malignant solid ovarian tumors on MRI exams. 

That’s according to a recent analysis published in Academic Radiology that compared the performance of three different models that varied in the features they utilized—clinical, radiomics or a combination of the two— to spot malignancy in solid ovarian tumors. In the paper, experts shared that the model that included both clinical and radiomics features recorded the highest AUC of the group, at .954, in addition to achieving impressive accuracy and precision measures. 

The models were trained and tested using images from MRI scans of 148 patients with 156 solid ovarian tumors. MRI is the modality of choice for distinguishing benign from malignant ovarian tumors, but interpreting these exams is not without its drawbacks, corresponding author of the study Li Guo, PhD, with the School of Medical Imaging at Tianjin Medical University in China, and co-authors explained: 

“MRI sequences contain a lot of information, but manual image screening is a large workload for radiologists and has subjective differences and misdiagnosis rates. The development of artificial intelligence in medical image could reduce the burden of radiologists and improve the efficiency of diagnosis.” 

Of the 156 tumors, 86 were benign and 70 malignant. Researchers used the imaging of the tumors to extract 12 clinical features and 1,612 radiomic features to develop their 3 models. 

While each model performed well, the model that combined clinical and radiomics features to predict malignancy exceeded the others, recording an AUC, accuracy, precision and sensitivity of 0.954, 0.839, 0.909 and 0.714 in test set. That same model also outperformed junior and senior radiologists in discriminating serous ovarian tumors. 

The experts concluded that their model and others like it could be advantageous to radiologists, given the somewhat precarious nature of classifying ovarian tumors. 

“The combined model which integrated qualitative clinical and radiomic information of the tumors, could help radiologists to discriminate between SBOTs and SMOTs.” 

More on malignant vs benign ovarian tumors: 

Algorithm performs at expert level when distinguishing between benign and malignant ovarian tumors

O-RADS externally validated for differentiating between benign and malignant ovarian lesions

These ultrasound features predict ovarian cancer

MRI accurately detects and reveals characteristics of serous borderline ovarian tumors

Reference: 

Yuemei Zheng, Hong Wang, Qiong Li, Haoran Sun, Li Guo. Discriminating Between Benign and Malignant Solid Ovarian Tumors Based on Clinical and Radiomic Features of MRI. Academic Radiology, 2022. 

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She joined Innovate Healthcare in 2021 and has since put her unique expertise to use in her editorial role with Health Imaging.

Around the web

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.